Seattle Genetics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Article By: Benzinga
Saturday, July 13, 2019 8:45 PM EDT
Last week was a quiet one for the biotech space with the exception of a few clinical trial readouts but the coming week features the beginning of earnings season, commencing with Johnson & Johnson.
In this article: JNJ, SGEN, ISRG, ABY
Read
Healthcare Investing Ideas Big And Small
Article By: Marc Lichtenfeld
Monday, January 15, 2018 9:00 PM EDT
With a dire need for growth, many in the industry expect the larger biotech and pharmaceutical companies to open their wallets and acquire smaller companies with novel drugs in development.
In this article: BMY, GSK, JNJ, PFE, AVXL, IMMP, BMRN, FOLD, SGEN, MBOT
Read
Seattle Genetics Upgraded To Overweight From Equal Weight At Barclays
Article By: The Fly
Friday, October 20, 2017 8:02 AM EDT
Barclays analyst Geoff Meacham upgraded Seattle Genetics to Overweight and raised his price target for the shares to $70 from $60.
In this article: SGEN Also: REGN
Read
5 Drug Stocks Well Poised To Beat Q2 Earnings Estimates
Article By: Zacks Investment Research
Thursday, July 13, 2017 4:58 PM EDT
The pharma/biotech sector has picked up this year after being battered by the drug pricing controversy in 2016. The first half has been pretty strong for companies in the space.
In this article: MRK, SGEN, VNDA, CELG, GILD
Read

PARTNER HEADLINES

Latest Tweets for $SGEN

No tweets yet!

$SGEN

Large Cap Biopharmaceuticals Performance Update 2018: Part 2
Harry Goldstein 2/20/2018 9:31:10 PM

Why did you decide to purchase $SGEN?

Seattle Genetics Receives FDA Halt On Several Phase 1 Studies
Caitlin Snow 1/3/2017 7:11:44 PM

A real tragedy, not just for $SGEN investors, but for the families of those who died as a result of the trials. How likely is it that the company can bounce back from something like this?

1 to 2 of 2 comments